BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care Alzheimer's disease, the most prevalent form of dementia, poses a ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...

(Reuters) - Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the ...

The clinical services giant Labcorp is rolling out its first blood test to help identify and confirm the signs of multiple neurodegenerative diseases and brain injury, including ALS, dementia and ...

Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide BURLINGTON, N.C., Oct 10, 2024 /PRNewswire/ -- ...

Labcorp launched a first-of-its-kind, at-home diabetes risk testing kit. Labcorp is the only commercial lab to offer Weavr Health’s Velvet blood collection device, according to a May 16 news release.

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...